Merrimack Pharmaceuticals
| Company type | Public |
|---|---|
| Nasdaq: MACK Russell Microcap Index component | |
| Industry | Pharmaceuticals |
| Founded | 2000 in Cambridge, Massachusetts |
| Headquarters | , United States |
Number of employees | 426 (2016) |
| Website | merrimack |
Merrimack Pharmaceuticals, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, United States. They specialize in developing drugs for the treatment of cancer.
Merrimack's first FDA-approved drug was approved in 2015; Onivyde, a liposome encapsulated version of irinotecan is used for treating pancreatic adenocarcinoma. It was approved for use in the European Union the following year.